Greater understanding of tumor biology has since led to the discovery that tumors with sensitizing EGFR mutations, particularly the somatic mutations in EGFR exons 19 and 21, respond favorably to EGFR TKIs compared with chemotherapy [5]. Here, EGFR is linked to neoplasm.